A phase 3, randomized, double-blind, placebo controlled, parallel group, 10-week study evaluating the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder

Trial Profile

A phase 3, randomized, double-blind, placebo controlled, parallel group, 10-week study evaluating the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2012

At a glance

  • Drugs Imagabalin (Primary)
  • Indications Generalised anxiety disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 27 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 25 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top